Montelukast in the treatment of asthma and beyond

References

• Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy59(5), 469–478 (2004).
   PubMed Web of Science ®Google Scholar
• Bjermer L. History and future perspectives of treating asthma as a systemic and small airways disease. Respir. Med.95(9), 703–719 (2001).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy63(Suppl. 86), 8–160 (2008).
   PubMed Web of Science ®Google Scholar
• Bjermer L. Time for a paradigm shift in asthma treatment: from relieving bronchospasm to controlling systemic inflammation. J. Allergy Clin. Immunol.120(6), 1269–1275 (2007).
   PubMed Web of Science ®Google Scholar
• Kyllönen H, Malmberg P, Remitz A et al. Respiratory symptoms, bronchial hyper-responsiveness, and eosinophilic airway inflammation in patients with moderate-to-severe atopic dermatitis. Clin. Exp. Allergy36(2), 192–197 (2006).
   PubMed Web of Science ®Google Scholar
• Ten Brinke A, Ouwerkerk ME, Zwinderman AH, Spinhoven P, Bel EH. Psychopathology in patients with severe asthma is associated with increased health care utilization. Am. J. Respir. Crit. Care Med.163(5), 1093–1096 (2001).
   PubMed Web of Science ®Google Scholar
• Leynaert B, Bousquet J, Neukirch C, Liard R, Neukirch F. Perennial rhinitis: an independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. J. Allergy Clin. Immunol.104(2 Pt 1), 301–304 (1999).
   PubMed Web of Science ®Google Scholar
• Guerra S, Sherrill DL, Martinez FD, Barbee RA. Rhinitis as an independent risk factor for adult-onset asthma. J. Allergy Clin. Immunol.109(3), 419–425 (2002).
   PubMed Web of Science ®Google Scholar
• Greisner WA, Settipane RJ, Settipane GA. Co-existence of asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Asthma Proc.19(4), 185–188 (1998).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Gaugris S, Kocevar VS et al. Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy corrected. Clin. Exp. Allergy35(6), 723–727 (2005).
   PubMed Web of Science ®Google Scholar
• Ponte EV, Franco R, Nascimento HF et al. Lack of control of severe asthma is associated with co-existence of moderate-to-severe rhinitis. Allergy63(5), 564–569 (2008).
   PubMed Web of Science ®Google Scholar
• Chanez P, Vignola AM, Vic P et al. Comparison between nasal and bronchial inflammation in asthmatic and control subjects. Am. J. Respir. Crit. Care Med.159(2), 588–595 (1999).
   PubMed Web of Science ®Google Scholar
• Gratziou C, Rovina N, Lignos M, Vogiatzis I, Roussos C. Exhaled nitric oxide in seasonal allergic rhinitis: influence of pollen season and therapy. Clin. Exp. Allergy31(3), 409–416 (2001).
   PubMed Web of Science ®Google Scholar
• de Benedictis FM, Vaccher S, de Benedictis D. Montelukast sodium for exercise-induced asthma. Drugs Today (Barc.)44(11), 845–855 (2008).
   PubMed Web of Science ®Google Scholar
• Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, Pavord ID. Mast-cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med.346(22), 1699–1705 (2002).
   PubMed Web of Science ®Google Scholar
• Balzar S, Chu HW, Strand M, Wenzel S. Relationship of small airway chymase-positive mast cells and lung function in severe asthma. Am. J. Respir. Crit. Care Med.171(5), 431–439 (2005).
   PubMed Web of Science ®Google Scholar
• Dolhnikoff M, da Silva LF, de Araujo BB et al. The outer wall of small airways is a major site of remodeling in fatal asthma. J. Allergy Clin. Immunol. (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Diamant Z, Boot JD, Virchow JC. Summing up 100 years of asthma. Respir. Med.101(3), 378–388 (2007).
   PubMed Web of Science ®Google Scholar
• Bateman ED, Boushey HA, Bousquet J et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am. J. Respir. Crit. Care Med.170(8), 836–844 (2004).
   PubMed Web of Science ®Google Scholar
• Bourdin A, Paganin F, Préfaut C, Kieseler D, Godard P, Chanez P. Nitrogen washout slope in poorly controlled asthma. Allergy61(1), 85–89 (2006).
   PubMed Web of Science ®Google Scholar
• Dworski R, Fitzgerald GA, Oates JA, Sheller JR. Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am. J. Respir. Crit. Care Med.149(4 Pt 1), 953–959 (1994).
   PubMed Web of Science ®Google Scholar
• Pavord ID, Ward R, Woltmann G, Wardlaw AJ, Sheller JR, Dworski R. Induced sputum eicosanoid concentrations in asthma. Am. J. Respir. Crit. Care Med.160(6), 1905–1909 (1999).
   PubMed Web of Science ®Google Scholar
• Feldberg W, Kellaway CH. Liberation of histamine and formation of lyscithin-like substances by cobra venom. J. Physiol.94, 187–226 (1938).
   PubMedGoogle Scholar
• Kellaway CH, Trethewie ER. The liberation of a slow reacting smooth-muscle stimulating substance in anaphylaxis. Q. J. Exp. Physiol.30(2), 121–145 (1940).
   Google Scholar
• Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors: cellular distribution and function in immune and inflammatory responses. J. Immunol.173(3), 1503–1510 (2004).
   PubMed Web of Science ®Google Scholar
• Peres CM, Aronoff DM, Serezani CH, Flamand N, Faccioli LH, Peters-Golden M. Specific leukotriene receptors couple to distinct G proteins to effect stimulation of alveolar macrophage host defense functions. J. Immunol.179(8), 5454–5461 (2007).
   PubMed Web of Science ®Google Scholar
• Lynch KR, O’Neill GP, Liu Q et al. Characterization of the human cysteinyl leukotriene CysLT1 receptor. Nature399(6738), 789–793 (1999).
   PubMed Web of Science ®Google Scholar
• Sarau HM, Ames RS, Chambers J et al. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol. Pharmacol.56(3), 657–663 (1999).
   PubMed Web of Science ®Google Scholar
• Hay DW. Pharmacology of leukotriene receptor antagonists. More than inhibitors of bronchoconstriction. Chest111(2 Suppl.), 35S–45S (1997).
   Google Scholar
• Yang G, Haczku A, Chen H et al. Transgenic smooth muscle expression of the human CysLT1 receptor induces enhanced responsiveness of murine airways to leukotriene D4. Am. J. Physiol. Lung Cell Mol. Physiol.286(5), L992–L1001 (2004).
   Google Scholar
• Laitinen LA, Laitinen A, Haahtela T, Vilkka V, Spur BW, Lee TH. Leukotriene E4 and granulocytic infiltration into asthmatic airways. Lancet341(8851), 989–990 (1993).
   PubMed Web of Science ®Google Scholar
• Diamant Z, Hiltermann JT, van Rensen EL et al. The effect of inhaled leukotriene D4 and methacholine on sputum cell differentials in asthma. Am. J. Respir. Crit. Care Med.155(4), 1247–1253 (1997).
   PubMed Web of Science ®Google Scholar
• Altraja S, Kadai M, Rekker E, Altraja A. Synthesis of tenascin and laminin beta2 chain in human bronchial epithelial cells is enhanced by cysteinyl leukotrienes via CysLT1 receptor. Respir. Res.9, 44 (2008).
   PubMedGoogle Scholar
• Abdulamir AS, Hafidh RR, Abubakar F. Different inflammatory mechanisms in lungs of severe and mild asthma: crosstalk of NF-κ-B, TGFβ1, Bax, Bcl-2, IL-4 and IgE. Scand. J. Clin. Lab. Invest. (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Wenzel SE, Larsen GL, Johnston K, Voelkel NF, Westcott JY. Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am. Rev. Respir. Dis.142(1), 112–119 (1990).
   PubMed Web of Science ®Google Scholar
• Diamant Z, Sampson AP. Anti-inflammatory mechanisms of leukotriene modulators. Clin. Exp. Allergy29(11), 1449–1453 (1999).
   PubMed Web of Science ®Google Scholar
• Georgitis JW, Matthews BL, Stone B. Chronic sinusitis: characterization of cellular influx and inflammatory mediators in sinus lavage fluid. Int. Arch. Allergy Immunol.106(4), 416–421 (1995).
   PubMed Web of Science ®Google Scholar
• Pawankar R, Zernotti ME. Rhinosinusitis in children and asthma severity. Curr. Opin. Allergy Clin. Immunol.9(2), 151–153 (2009).
   PubMed Web of Science ®Google Scholar
• Arshad SH, Tariq SM, Matthews S, Hakim E. Sensitization to common allergens and its association with allergic disorders at age 4 years: a whole population birth cohort study. Pediatrics108(2), E33 (2001).
   PubMed Web of Science ®Google Scholar
• Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J. Allergy Clin. Immunol.98(6 Pt 1), 1051–1057 (1996).
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Gangnon RE, Evans MD et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am. J. Respir. Crit. Care Med.178(7), 667–672 (2008).
   PubMed Web of Science ®Google Scholar
• Kusel MM, de Klerk NH, Kebadze T et al. Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J. Allergy Clin. Immunol.119(5), 1105–1110 (2007).
   PubMed Web of Science ®Google Scholar
• Piedimonte G, Renzetti G, Auais A et al. Leukotriene synthesis during respiratory syncytial virus bronchiolitis: influence of age and atopy. Pediatr. Pulmonol.40, 285–291 (2005).
   PubMed Web of Science ®Google Scholar
• De Lepeleire I, Reiss TF, Rochette F et al. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma. Clin. Pharmacol. Ther.61(1), 83–92 (1997).
   PubMed Web of Science ®Google Scholar
• Reiss TF, Sorkness CA, Stricker W et al. Effects of montelukast (MK-0476); a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax52(1), 45–48 (1997).
   PubMed Web of Science ®Google Scholar
• Kelly MM, Chakir J, Vethanayagam D et al. Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest130(3), 741–753 (2006).
   PubMed Web of Science ®Google Scholar
• Migoya E, Kearns GL, Hartford A et al. Pharmacokinetics of montelukast in asthmatic patients 6 to 24 months old. J. Clin. Pharmacol.44(5), 487–494 (2004).
   PubMed Web of Science ®Google Scholar
• Sampson AP, Diamant Z. Monograph on montelukast. J. Drug Evaluation1(2), 53–88 (2002).
   Google Scholar
• Muijsers RB, Noble S. Spotlight on montelukast in asthma in children 2 to 14 years of age. Am. J. Respir. Med.1(3), 225–228 (2002).
   PubMedGoogle Scholar
• Chiba M, Xu X, Nishime JA, Balani SK, Lin JH. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab. Dispos.25(9), 1022–1031 (1997).
   PubMed Web of Science ®Google Scholar
• Ravasi S, Capra V, Panigalli T, Rovati GE, Nicosia S. Pharmacological differences among CysLT(1) receptor antagonists with respect to LTC(4) and LTD(4) in human lung parenchyma. Biochem. Pharmacol.63(8), 1537–1546 (2002).
   PubMed Web of Science ®Google Scholar
• Jones TR, Labelle M, Belley M et al. Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist. Can. J. Physiol. Pharmacol.73(2), 191–201 (1995).
   PubMed Web of Science ®Google Scholar
• Dahlén SE, Malmström K, Nizankowska E et al. Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. Am. J. Respir. Crit. Care Med.165(1), 9–14 (2002).
   PubMed Web of Science ®Google Scholar
• Diamant Z, Grootendorst DC, Veselic-Charvat M et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin. Exp. Allergy29(1), 42–51 (1999).
   PubMed Web of Science ®Google Scholar
• Leff JA, Busse WW, Pearlman D et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N. Engl. J. Med.339(3), 147–152 (1998).
   PubMed Web of Science ®Google Scholar
• Villaran C, O’Neill SJ, Helbling A et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J. Allergy Clin. Immunol.104(3 Pt 1), 547–553 (1999).
   PubMed Web of Science ®Google Scholar
• Edelman JM, Turpin JA, Bronsky EA et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann. Intern. Med.132(2), 97–104 (2000).
   PubMed Web of Science ®Google Scholar
• Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir. Med.98(11), 1051–1062 (2004).
   PubMed Web of Science ®Google Scholar
• Pizzichini E, Leff JA, Reiss TF et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur. Respir. J.14(1), 12–18 (1999).
   PubMed Web of Science ®Google Scholar
• Jayaram L, Pizzichini E, Lemière C et al. Steroid naive eosinophilic asthma: anti-inflammatory effects of fluticasone and montelukast. Thorax60(2), 100–105 (2005).
   PubMed Web of Science ®Google Scholar
• Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet357(9273), 2007–2011 (2001).
   PubMed Web of Science ®Google Scholar
• Bjermer L, Bisgaard H, Bousquet J et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ327(7420), 891 (2003).
   PubMed Web of Science ®Google Scholar
• Braccioni F, Dorman SC, O’Byrne PM et al. The effect of cysteinyl leukotrienes on growth of eosinophil progenitors from peripheral blood and bone marrow of atopic subjects. J. Allergy Clin. Immunol.110(1), 96–101 (2002).
   PubMed Web of Science ®Google Scholar
• Ghiro L, Zanconato S, Rampon O, Piovan V, Pasquale MF, Baraldi E. Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children. Eur. Respir. J.20(3), 630–634 (2002).
   PubMed Web of Science ®Google Scholar
• Wahn U, Dass SB. Review of recent results of montelukast use as a monotherapy in children with mild asthma. Clin. Ther.30, 1026–1035 (2008).
   PubMed Web of Science ®Google Scholar
• Holgate ST, Peters-Golden M, Panettieri RA, Henderson WR. Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. J. Allergy Clin. Immunol.111(Suppl. 1), S18–S34 (2003).
   PubMedGoogle Scholar
• Walters EH, Reid DW, Johns DP, Ward C. Nonpharmacological and pharmacological interventions to prevent or reduce airway remodelling. Eur. Respir. J.30(3), 574–588 (2007).
   PubMed Web of Science ®Google Scholar
• Riccioni G, Vecchia RD, D’Orazio N, Sensi S, Guagnano MT. Comparison of montelukast and budesonide on bronchial reactivity in subjects with mild–moderate persistent asthma. Pulm. Pharmacol. Ther.16(2), 111–114 (2003).
   PubMed Web of Science ®Google Scholar
• Zeidler MR, Kleerup EC, Goldin JG et al. Montelukast improves regional air-trapping due to small airways obstruction in asthma. Eur. Respir. J.27(2), 307–315 (2006).
   PubMed Web of Science ®Google Scholar
• Stelmach I, Grzelewski T, Bobrowska-Korzeniowska M, Stelmach P, Kuna P. A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma. Pulm. Pharmacol. Ther.20(6), 691–700 (2007).
   PubMed Web of Science ®Google Scholar
• Fritscher LG, Rodrigues MT, Zamel N, Chapman KR. The effect of montelukast on exhaled nitric oxide of alveolar and bronchial origin in inhaled corticosteroid-treated asthma. Respir. Med.103(2), 296–300 (2009).
   PubMed Web of Science ®Google Scholar
• Currie GP, McLaughlin K. The expanding role of leukotriene receptor antagonists in chronic asthma. Ann. Allergy Asthma Immunol.97(6), 731–741 (2006).
   PubMed Web of Science ®Google Scholar
• Bjermer L, Diamant Z. Complementary therapy in asthma: inhaled corticosteroids and what? Curr. Opin. Pulm. Med.15(1), 46–51 (2009).
   PubMed Web of Science ®Google Scholar
• Kraft M, Cairns CB, Ellison MC, Pak J, Irvin C, Wenzel S. Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast. Chest130(6), 1726–1732 (2006).
   PubMed Web of Science ®Google Scholar
• Rosi E, Ronchi MC, Grazzini M, Duranti R, Scano G. Sputum analysis, bronchial hyperresponsiveness, and airway function in asthma: results of a factor analysis. J. Allergy Clin. Immunol.103(2 Pt 1), 232–237 (1999).
   PubMed Web of Science ®Google Scholar
• Kraft M, Pak J, Martin RJ, Kaminsky D, Irvin CG. Distal lung dysfunction at night in nocturnal asthma. Am. J. Respir. Crit. Care Med.163(7), 1551–1556 (2001).
   PubMed Web of Science ®Google Scholar
• Boot JD, Panzner P, Diamant Z. A critical appraisal of methods used in early clinical development of novel drugs for the treatment of asthma. Pulm. Pharmacol. Ther.20(3), 201–219 (2007).
   PubMed Web of Science ®Google Scholar
• Boot JD, Chandoesing P, de Kam ML et al. Applicability and reproducibility of biomarkers for the evaluation of anti-inflammatory therapy in allergic rhinitis. J. Invest. Allergol. Clin. Immunol.18(6), 433–442 (2008).
   PubMed Web of Science ®Google Scholar
• Noonan MJ, Chervinsky P, Brandon M et al. Montelukast, a potent leukotriene receptor antagonist, causes dose-related improvements in chronic asthma. Montelukast Asthma Study Group. Eur. Respir. J.11(6), 1232–1239 (1998).
   PubMed Web of Science ®Google Scholar
• Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch. Intern. Med.158(11), 1213–1220 (1998).
   PubMed Web of Science ®Google Scholar
• Malmstrom K, Rodriguez-Gomez G, Guerra J et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann. Intern. Med.130(6), 487–495 (1999).
   PubMed Web of Science ®Google Scholar
• Israel E, Chervinsky PS, Friedman B et al. Effects of montelukast and beclomethasone on airway function and asthma control. J. Allergy Clin. Immunol.110(6), 847–854 (2002).
   PubMed Web of Science ®Google Scholar
• Baumgartner RA, Martinez G, Edelman JM et al. Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur. Respir. J.21(1), 123–128 (2003).
   PubMed Web of Science ®Google Scholar
• Kanniess F, Richter K, Böhme S, Jörres RA, Magnussen H. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur. Respir. J.20(4), 853–858 (2002).
   PubMed Web of Science ®Google Scholar
• Zeiger RS, Szefler SJ, Phillips BR et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J. Allergy Clin. Immunol.117(1), 45–52 (2006).
   PubMed Web of Science ®Google Scholar
• Vaquerizo MJ, Casan P, Castillo J et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax58(3), 204–210 (2003).
   PubMed Web of Science ®Google Scholar
• Price DB, Hernandez D, Magyar P et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax58(3), 211–216 (2003).
   PubMed Web of Science ®Google Scholar
• Price DB, Swern A, Tozzi CA, Philip G, Polos P. Effect of montelukast on lung function in asthma patients with allergic rhinitis: analysis from the COMPACT trial. Allergy61(6), 737–742 (2006).
   PubMed Web of Science ®Google Scholar
• Kaminsky DA, Bates JH, Irvin CG. Effects of cool, dry air stimulation on peripheral lung mechanics in asthma. Am. J. Respir. Crit. Care Med.162(1), 179–186 (2000).
   PubMed Web of Science ®Google Scholar
• Steinshamn S, Sandsund M, Sue-Chu M, Bjermer L. Effects of montelukast and salmeterol on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction. Chest126(4), 1154–1160 (2004).
   PubMed Web of Science ®Google Scholar
• Meltzer EO. Clinical evidence for antileukotriene therapy in the management of allergic rhinitis. Ann. Allergy Asthma Immunol.88(4 Suppl. 1), 23–29 (2002).
   PubMed Web of Science ®Google Scholar
• Wilson AM, Orr LC, Coutie WJ, Sims EJ, Lipworth BJ. A comparison of once daily fexofenadine versus the combination of montelukast plus loratadine on domiciliary nasal peak flow and symptoms in seasonal allergic rhinitis. Clin. Exp. Allergy32(1), 126–132 (2002).
   PubMed Web of Science ®Google Scholar
• Nayak AS, Philip G, Lu S, Malice MP, Reiss TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann. Allergy Asthma Immunol.88(6), 592–600 (2002).
   PubMed Web of Science ®Google Scholar
• Philip G, Nayak AS, Berger WE et al. The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr. Med. Res. Opin.20(10), 1549–1558 (2004).
   PubMed Web of Science ®Google Scholar
• Grossman J. One airway, one disease. Chest111(2 Suppl.), 11S–16S (1997).
   Google Scholar
• Rönmark E, Lindberg A, Watson L, Lundbäck B. Outcome and severity of adult onset asthma – report from the obstructive lung disease in northern Sweden studies (OLIN). Respir. Med.101(11), 2370–2377 (2007).
   PubMed Web of Science ®Google Scholar
• Murray CS. Can inhaled corticosteroids influence the natural history of asthma? Curr. Opin. Allergy Clin. Immunol.8(1), 77–81 (2008).
   PubMed Web of Science ®Google Scholar
• Selroos O. Effect of disease duration on dose-response of inhaled budesonide in asthma. Respir. Med.102(7), 1065–1072 (2008).
   PubMed Web of Science ®Google Scholar
• Berry M, Hargadon B, Morgan A et al. Alveolar nitric oxide in adults with asthma: evidence of distal lung inflammation in refractory asthma. Eur. Respir. J.25(6), 986–991 (2005).
   PubMed Web of Science ®Google Scholar
• Kato J, Kohyama T, Okazaki H et al. Leukotriene D4 potentiates fibronectin-induced migration of human lung fibroblasts. Clin. Immunol.117(2), 177–181 (2005).
   PubMed Web of Science ®Google Scholar
• Panettieri RA, Tan EM, Ciocca V, Luttmann MA, Leonard TB, Hay DW. Effects of LTD4 on human airway smooth muscle cell proliferation, matrix expression, and contraction in vitro: differential sensitivity to cysteinyl leukotriene receptor antagonists. Am. J. Respir. Cell. Mol. Biol.19(3), 453–461 (1998).
   PubMed Web of Science ®Google Scholar
• Cai Y, Bjermer L, Halstensen TS. Bronchial mast cells are the dominating LTC4S-expressing cells in aspirin-tolerant asthma. Am. J. Respir. Cell. Mol. Biol.29(6), 683–693 (2003).
   PubMed Web of Science ®Google Scholar
• Henderson WR, Tang LO, Chu SJ et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. Am. J. Respir. Crit. Care Med.165(1), 108–116 (2002).
   PubMed Web of Science ®Google Scholar
• Henderson WR, Chiang GK, Tien YT, Chi EY. Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. Am. J. Respir. Crit. Care Med.173(7), 718–728 (2006).
   PubMed Web of Science ®Google Scholar
• Pifferi M, Caramella D, Ragazzo V, De Marco E, Pietrobelli A, Boner AL. Montelukast and airway remodeling in children with chronic persistent asthma: an open study. Pediatr. Allergy Immunol.15(5), 472–473 (2004).
   PubMed Web of Science ®Google Scholar
• Knorr B, Matz J, Bernstein JA et al. Montelukast for chronic asthma in 6- to 14-year-old children: a randomized, double-blind trial. Pediatric Montelukast Study Group. JAMA279(15), 1181–1186 (1998).
   PubMed Web of Science ®Google Scholar
• Becker A, Swern A, Tozzi CA, Yu Q, Reiss T, Knorr B. Montelukast in asthmatic patients 6 years-14 years old with an FEV1 > 75%. Curr. Med. Res. Opin.20(10), 1651–1659 (2004).
   PubMed Web of Science ®Google Scholar
• Simons FE, Villa JR, Lee BW et al. Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J. Pediatr.138(5), 694–698 (2001).
   PubMed Web of Science ®Google Scholar
• Karaman O, Sünneli L, Uzuner N et al. Evaluation of montelukast in 8 to 14 year old children with mild persistent asthma and compared with inhaled corticosteroids. Allergol. Immunopathol. (Madr.)32(1), 21–27 (2004).
   PubMedGoogle Scholar
• Taylor IK, Wellings R, Taylor GW, Fuller RW. Urinary leukotriene E4 excretion in exercise-induced asthma. J. Appl. Physiol.73(2), 743–748 (1992).
   PubMed Web of Science ®Google Scholar
• Carraro S, Corradi M, Zanconato S et al. Exhaled breath condensate cysteinyl leukotrienes are increased in children with exercise-induced bronchoconstriction. J. Allergy Clin. Immunol.115(4), 764–770 (2005).
   PubMed Web of Science ®Google Scholar
• Peroni DG, Piacentini GL, Pietrobelli A et al. The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children. Eur. Respir. J.20(1), 104–107 (2002).
   PubMed Web of Science ®Google Scholar
• Melo RE, Solé D, Naspitz CK. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate-phase and late-phase responses. J. Allergy Clin. Immunol.111(2), 301–307 (2003).
   PubMed Web of Science ®Google Scholar
• Kim JH, Lee SY, Kim HB et al. Prolonged effect of montelukast in asthmatic children with exercise-induced bronchoconstriction. Pediatr. Pulmonol.39(2), 162–166 (2005).
   PubMed Web of Science ®Google Scholar
• de Benedictis FM, del Giudice MM, Forenza N, Decimo F, de Benedictis D, Capristo A. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur. Respir. J.28(2), 291–295 (2006).
   PubMed Web of Science ®Google Scholar
• Stelmach I, Grzelewski T, Majak P, Jerzynska J, Stelmach W, Kuna P. Effect of different antiasthmatic treatments on exercise-induced bronchoconstriction in children with asthma. J. Allergy Clin. Immunol.121(2), 383–389 (2008).
   PubMed Web of Science ®Google Scholar
• Phipatanakul W, Greene C, Downes SJ et al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann. Allergy Asthma Immunol.91(1), 49–54 (2003).
   PubMed Web of Science ®Google Scholar
• Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics116(2), 360–369 (2005).
   PubMed Web of Science ®Google Scholar
• Kumar V, Ramesh P, Lodha R, Pandey RM, Kabra SK. Montelukast vs. inhaled low-dose budesonide as monotherapy in the treatment of mild persistent asthma: a randomized double blind controlled trial. J. Trop. Pediatr.53(5), 325–330 (2007).
   PubMed Web of Science ®Google Scholar
• Spahn JD, Covar RA, Jain N et al. Effect of montelukast on peripheral airflow obstruction in children with asthma. Ann. Allergy Asthma Immunol.96(4), 541–549 (2006).
   PubMed Web of Science ®Google Scholar
• Nieto A, Pamies R, Oliver F, Medina A, Caballero L, Mazon A. Montelukast improves pulmonary function measured by impulse oscillometry in children with asthma (Mio study). Respir. Med.100(7), 1180–1185 (2006).
   PubMed Web of Science ®Google Scholar
• Verini M, Peroni DG, Piacentini GL et al. Comparison of add-on therapy to inhaled fluticasone propionate in children with asthma: residual volume and exhaled nitric oxide as outcome measures. Allergy Asthma Proc.28(6), 691–694 (2007).
   PubMed Web of Science ®Google Scholar
• Miraglia del Giudice M, Piacentini GL, Capasso M et al. Formoterol, montelukast, and budesonide in asthmatic children: effect on lung function and exhaled nitric oxide. Respir. Med.101(8), 1809–1813 (2007).
   PubMed Web of Science ®Google Scholar
• Rabinovitch N, Strand M, Stuhlman K, Gelfand EW. Exposure to tobacco smoke increases leukotriene E4-related albuterol usage and response to montelukast. J. Allergy Clin. Immunol.121(6), 1365–1371 (2008).
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Phillips BR, Martinez FD et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J. Allergy Clin. Immunol.115(2), 233–242 (2005).
   PubMed Web of Science ®Google Scholar
• Knorr B, Franchi LM, Bisgaard H et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics108(3), E48 (2001).
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Zielen S, Garcia-Garcia ML et al. Montelukast reduces asthma exacerbations in 2- to 5-year-old children with intermittent asthma. Am. J. Respir. Crit. Care Med.171(4), 315–322 (2005).
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Flores-Nunez A, Goh A et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am. J. Respir. Crit. Care Med.178(8), 854–860 (2008).
   PubMed Web of Science ®Google Scholar
• Davies GM, Dasbach EJ, Santanello NC, Knorr BA, Bratton DL. The effect of montelukast versus usual care on health care resource utilization in children aged 2 to 5 years with asthma. Clin. Ther.26(11), 1895–1904 (2004).
   PubMed Web of Science ®Google Scholar
• Kooi EM, Schokker S, Marike Boezen H et al. Fluticasone or montelukast for preschool children with asthma-like symptoms: randomized controlled trial. Pulm. Pharmacol. Ther.21(5), 798–804 (2008).
   PubMed Web of Science ®Google Scholar
• Straub DA, Moeller A, Minocchieri S et al. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur. Respir. J.25(2), 289–294 (2005).
   PubMed Web of Science ®Google Scholar
• Hakim F, Vilozni D, Adler A, Livnat G, Tal A, Bentur L. The effect of montelukast on bronchial hyperreactivity in preschool children. Chest131(1), 180–186 (2007).
   PubMed Web of Science ®Google Scholar
• Robertson CF, Price D, Henry R et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am. J. Respir. Crit. Care Med.175(4), 323–329 (2007).
   PubMed Web of Science ®Google Scholar
• Johnston NW, Mandhane PJ, Dai J et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics120(3), e702–e712 (2007).
   PubMed Web of Science ®Google Scholar
• Amirav I, Luder AS, Kruger N et al. A double-blind, placebo-controlled, randomized trial of montelukast for acute bronchiolitis. Pediatrics122(6), e1249–e1255 (2008).
   PubMed Web of Science ®Google Scholar
• Bacharier LB, Phillips BR, Zeiger RS et al. Episodic use of an inhaled corticosteroid or leukotriene receptor antagonist in preschool children with moderate-to-severe intermittent wheezing. J. Allergy Clin. Immunol.122(6), 1127–1135.e8 (2008).
   PubMed Web of Science ®Google Scholar
• Brand PL, Baraldi E, Bisgaard H et al. Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach. Eur. Respir. J.32(4), 1096–1110 (2008).
   PubMed Web of Science ®Google Scholar
• Barnes N, Thomas M, Price D, Tate H. The national montelukast survey. J. Allergy Clin. Immunol.115(1), 47–54 (2005).
   PubMed Web of Science ®Google Scholar
• Dal Negro RW, Borderias L, Zhang Q et al. Rates of asthma attacks in patients with previously inadequately controlled mild asthma treated in clinical practice with combination drug therapy: an exploratory post-hoc analysis. BMC Pulm. Med.9, 10 (2009).
   PubMedGoogle Scholar
• Korn D, Van den Brande P, Potvin E, Dramaix M, Herbots E, Peché R. Efficacy of add-on montelukast in patients with non-controlled asthma: a Belgian open-label study. Curr. Med. Res. Opin.25(2), 489–497 (2009).
   PubMed Web of Science ®Google Scholar
• Storms W, Michele TM, Knorr B et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin. Exp. Allergy31(1), 77–87 (2001).
   PubMed Web of Science ®Google Scholar
• Chervinsky P, Philip G, Malice MP et al. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann. Allergy Asthma Immunol.92(3), 367–373 (2004).
   PubMed Web of Science ®Google Scholar
• Bakhireva LN, Jones KL, Schatz M et al. Safety of leukotriene receptor antagonists in pregnancy. J. Allergy Clin. Immunol.119(3), 618–625 (2007).
   PubMed Web of Science ®Google Scholar
• Becker AB, Kuznetsova O, Vermeulen J et al. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Ann. Allergy Asthma Immunol.96(6), 800–807 (2006).
   PubMed Web of Science ®Google Scholar
• Pedersen S, Agertoft L, Williams-Herman D et al. Placebo-controlled study of montelukast and budesonide on short-term growth in prepubertal asthmatic children. Pediatr. Pulmonol.42(9), 838–843 (2007).
   PubMed Web of Science ®Google Scholar
• Loughlin JE, Cole JA, Rothman KJ, Johnson ES. Prevalence of serious eosinophilia and incidence of Churg–Strauss syndrome in a cohort of asthma patients. Ann. Allergy Asthma Immunol.88(3), 319–325 (2002).
   PubMed Web of Science ®Google Scholar
• Hauser T, Mahr A, Metzler C et al. The leucotriene receptor antagonist montelukast and the risk of Churg-Strauss syndrome: a case-crossover study. Thorax63(8), 677–682 (2008).
   PubMed Web of Science ®Google Scholar
• Holbrook JT, Harik-Khan R. Montelukast and emotional well-being as a marker for depression: results from 3 randomized, double-masked clinical trials. J. Allergy Clin. Immunol.122(4), 828–829 (2008).
   PubMed Web of Science ®Google Scholar
• Strine TW, Mokdad AH, Balluz LS, Berry JT, Gonzalez O. Impact of depression and anxiety on quality of life, health behaviors, and asthma control among adults in the United States with asthma, 2006. J. Asthma45(2), 123–133 (2008).
   PubMed Web of Science ®Google Scholar
• Holgate S, Bisgaard H, Bjermer L et al. The Brussels Declaration: the need for change in asthma management. Eur. Respir. J.32(6), 1433–1442 (2008).
   PubMed Web of Science ®Google Scholar
• Wohlsen A, Martin C, Vollmer E et al. The early allergic response in small airways of human precision-cut lung slices. Eur. Respir. J.21(6), 1024–1032 (2003).
   PubMed Web of Science ®Google Scholar
• ten Brinke A, Sterk PJ, Masclee AA et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur. Respir. J.26(5), 812–818 (2005).
   PubMed Web of Science ®Google Scholar
• Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am. J. Respir. Crit. Care Med.178(3), 218–224 (2008).
   PubMed Web of Science ®Google Scholar